Alkermes to acquire Avadel for up to $2.1 billion

(Reuters) -Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company’s approved excessive daytime sleepiness drug.

(Reporting by Sriparna Roy in Bengaluru; Editing by Tasim Zahid)